Clinical experience of ceritinib in patients who progressed on alectinib is limited. In this prospective phase II study, we evaluated the activity of ceritinib in alectinib-pre- -
| INTRODUCTION
Anaplastic lymphoma kinase (ALK)-rearrangements serve as a key oncogenic driver and occur in approximately 3%-7% of patients with non-small-cell lung cancer (NSCLC). 1, 2 Crizotinib, the first ALK inhibitor approved by the US Food and Drug Administration (FDA) (August 2011), 3 significantly prolonged progression-free survival (PFS) compared with chemotherapy in patients with untreated and chemotherapy-treated advanced ALK-positive NSCLC. 4, 5 Crizotinib received approval in Japan in March 2012 in any line of treatment and was approved in the European Union in October 2012, in the first-line setting. 6, 7 Despite the efficacy of crizotinib, emergence of resistance to crizotinib is almost inevitable after a median of 10.9 months, 4 which could be due to secondary mutations or amplification of ALK, activation of downstream molecules, or poor penetration to the brain. 4, 8 To overcome crizotinib resistance, several next-generation ALK inhibitors have been developed, including ceritinib, alectinib, brigatinib, and lorlatinib. 9 Alectinib, a next-generation ALK inhibitor was first approved in Japan in July 2014 for ALK-inhibitor-naïve patients with ALK-rearranged (ALK-positive) NSCLC, based on the results from the AF-001JP study. 10 Furthermore, the results from two phase III trials (J-ALEX and ALEX) showed superior efficacy and lower toxicity of alectinib versus crizotinib in primary treatment of ALK-positive NSCLC. 11, 12 However, treatment options are lacking in patients who develop resistance to alectinib and thus post-alectinib ALK inhibitor therapy is of high clinical interest.
Ceritinib, a selective oral ALK inhibitor, is approved for the treatment of patients with metastatic ALK-positive NSCLC. 13 In randomized, global phase III trials, ceritinib showed a statistically significant and clinically meaningful improvement in PFS versus chemotherapy in patients with advanced ALK-positive NSCLC who were treatmentnaïve (ASCEND-4 study) 14 or previously treated with crizotinib and with 1 or 2 prior chemotherapy regimens (ASCEND-5 study). 15 Although the original approvals were at a dose of 750 mg/day under fasted conditions, the revised recommended dose of 450 mg/day with food was approved in the USA in December 2017 13 and in the European Union in May 2018.
Each ALK inhibitor (eg, ceritinib, alectinib, and crizotinib) has different IC 50 for each mutation. Preclinical data have shown that ceritinib is active against mutations that are resistant to alectinib. 16 In the phase I study of ceritinib in Japanese patients with ALK-positive NSCLC, 2 of 4 patients pretreated with alectinib showed a partial response (PR) with ceritinib. 17 These preliminary preclinical and clinical data of ceritinib indicate the possibility of expanding therapeutic options for patients with ALK-positive NSCLC who have failed prior alectinib. However, none of the studies prospectively assessed the efficacy and safety of ceritinib in patients with ALK-positive NSCLC who progressed on alectinib. Here, we present the results from the phase II ASCEND-9 study, which investigated the activity of ceritinib in these patients. Patients were excluded if they had known hypersensitivity to any of the excipients of ceritinib; history of carcinomatous meningitis; history of interstitial lung disease or interstitial pneumonitis;
| MATERIALS AND METHODS

| Study population
received thoracic radiotherapy to lung fields ≤4 weeks prior to starting the study treatment or had not recovered from radiotherapyrelated toxicities; major surgery within 4 weeks prior to the first dose of study drug or had recovered from side-effects of such procedure; a concurrent malignancy or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years (except completely resected basal cell and squamous cell skin cancers, and completely resected carcinoma in situ of any type); a history of pancreatitis or history of increased amylase or lipase as a result of pancreatic disease; clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months), impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of ceritinib.
The study protocol and all amendments were reviewed by the independent ethics committee or institutional review board for each center. This study was conducted according to the ethical principles of the Declaration of Helsinki and the Good Clinical Practice guidelines. Written informed consent was obtained from each patient before enrollment.
| Study design
This was a single-arm, open-label, multicenter, phase II study conducted at 9 centers in Japan (NCT02450903 
| Assessments
Tumor assessments were carried out by local investigators using computed tomography (CT) or magnetic resonance imaging (MRI) according to RECIST 1.1 at baseline; cycle 3 day 1, then every 8 weeks, and end of treatment (EOT) visit during treatment phase; and every 8 weeks following EOT until disease progression. Routine follow-up brain MRI or CT scans were carried out at cycle 3 and then every 8 weeks only in patients with brain metastases at baseline.
All AE reported were recorded and graded according to CTCAE, version 4.03. All patients were followed up for AE and serious AE (SAE) for at least 30 days following discontinuation of ceritinib treatment. 
| Molecular tumor analyses
| Statistical analysis
The primary analysis of study data was conducted at the time when all patients had either completed ≥6 cycles of treatment or discon- for patients with a confirmed response (CR or PR). The OS rate with 95% CI at 12 months was estimated using the Kaplan-Meier method.
If a patient was alive at the date of analysis cutoff or lost to follow up, OS was censored at the last contact date prior to the cutoff date. Safety outcomes were summarized descriptively. 
| RESULTS
| Patient disposition
| Efficacy
The best overall responses are reported in Table 2 . ORR by investigator review was 25.0% (95% CI: 8.7-49.1), whereas DCR was 70.0% (95% CI: 45.7-88.1). Among patients with measurable disease at baseline and ≥1 valid post-baseline assessment, 70.6% (12/17) had decrease in tumor burden from baseline by investigator review ( Figure 1A ). Among the responders, median time to first response by investigator assessment was 1.8 months (range: 1.8-2.0), and median DOR by investigator assessment was 6.3 months (95% CI: 3.5-9.2), with 3 of 5 (60.0%) patients having an event (PD for all 3 patients).
For each patient, treatment exposure and doses of ceritinib received, Table 3) showed CR. Figure S1 shows pre-ceritinib and 2 months post-ceritinib treatment scan images, illustrating regression of the target lesion in a patient (Patient 5 in Table 3 ) who was previously treated with first-line chemotherapy, second-line crizotinib (best response: PR), and third-line alectinib (best response: PR). NGS analysis of tissue sample from the progressed liver lesion before ceritinib indicated an L1196M mutation.
To characterize genetic profile/mutations in NSCLC tumors and ctDNA, we carried out Illumina-based Pan-Cancer gene assay for archival tumor at screening visit and for ctDNA at cycle 1 day 1 (C1D1) and EOT. More gene rearrangements and mutations were found in plasma samples (ctDNA) than in archival tumor samples.
Archival tumor samples were available from 6 patients for NGS anal- or G1269A at C1D1) was stable disease or PD, whereas the best response in the patient who had ALK L1196M mutation was PR.
At EOT, G1202R mutation was newly emerged in 2 patients (Patients 6 and 8).
| Safety
Median duration of ceritinib exposure was 3.7 months (range: 0.4-15.1), with a median relative dose intensity of 68.6% (range: 30.3%-100%). All patients experienced at least 1 AE, with 10 (50.0%) patients reporting an SAE irrespective of relationship to study drug.
The most frequently (>50%) reported all-causality AE were diarrhea (85.0%), nausea (80.0%), and vomiting (65.0%) ( Among the 5 responders in the present study, 4 had been treated with 2 or more prior regimens of medications, including alectinib, and 4 had been treated with alectinib as the last therapy prior to study enrollment. Interestingly, among the responders, duration between discontinuing alectinib and start of ceritinib treatment was only 1-3 days. Of note, 1 responder to ceritinib with a best overall response of PR had an L1196M ALK mutation known to be crizotinib resistant. Preclinical studies have shown that both ceritinib and alectinib are active against L1196 mutation with different IC 50 values. 22, 23 In non-responders, based on biomarker data and patients' demographics information, no specific characteristics of patients were identified. To better understand the activity of ceritinib in alectinib-resistant patients, further biomarker analysis is warranted, but we can speculate that ceritinib efficacy in alectinib-resistant patients could be a result of specific molecular alterations that impair alectinib binding to ALK. 16 We determined the DNA gene profile in tumor tissue and ctDNA in NSCLC patients. The ALK gene mutations identified are consistent with the reported resistance mutations for patients treated with alectinib or crizotinib. 24 From ctDNA we can detect mutations that are not in the formalin fixed paraffin embedded (FFPE) tumor because ctDNA is a collection of mutations that might come from different sites because of tumor heterogeneity. 25 As the numbers of patients were small in the present study, further study will be required to investigate the relationship between the identified multiple gene alterations and clinical outcomes. improve the relative dose intensity on account of a better gastrointestinal safety profile and more favorable benefit/risk profile.
In the phase I study of lorlatinib, ORR in patients who received at least 1 prior line of alectinib (N = 74) was 35.1%. 30 We acknowledge the activity of lorlatinib in alectinib-pretreated patients with ALK-positive NSCLC; however, comparison with our study is limited by different types of prior therapies (tyrosine kinase inhibitors and/or chemotherapy) received. Other limitations of our study include the small sample size and the fact that this was not a controlled trial comparing other ALK inhibitors or chemotherapy in this setting. As a result T A B L E 4 All-causality adverse events reported in ≥20.0% of patients of the small sample size, it was also very difficult to identify specific patient characteristics for the responders and non-responders.
In this phase II study, ceritinib showed rapid and meaningful antitumor activity in ALK-rearranged, advanced NSCLC patients who progressed on prior therapy with alectinib including patients who experienced immediate progression on prior alectinib. Responders to ceritinib included patients who received prior crizotinib in addition to alectinib and who had 2 or more lines of prior therapies. Safety profile of ceritinib was consistent with that reported in previous studies, and no new or unexpected safety concerns were identified. Overall, ceritinib could be considered as one of the treatment options for patients with ALK-positive NSCLC who progressed on alectinib.
ACKNOWLEDGMENTS
This study was sponsored by Novartis Pharma K.K., Tokyo, Japan.
We thank Pushkar Narvilkar and Shiva Krishna Rachamadugu, Novartis Healthcare Pvt. Ltd, for providing medical editorial assistance with this manuscript.
CONF LICTS OF INTEREST
Annual value of remuneration received: Masayuki Ito from Novartis Pharma K.K. (employment). Koichi Ayukawa from Novartis Pharma
